Brian Plew is the head of Business Development for the Asymptomatic Testing Solutions business unit at Thermo Fisher Scientific. He has a wealth of global public health experience from having supported infectious disease screening and surveillance programs, which include both the H1N1 and SARS-CoV-2 pandemics. Brian?s pioneering work in public health and diagnostics includes having partnered with the US CDC and the Association of Public Health Laboratories in 2008 to lead the commercial effort that submitted to the American FDA the first ever premarket notification for an Influenza diagnostic. ?Back-to-Life? testing is the focus of his current role. This includes helping to restore safe air travel and working to minimize the effects of the pandemic on companies and the passengers that depend on them. Brian has also worked with the Department of Homeland Security to develop standards for pathogen detection. Mr. Plew aspires to offer his talent and deep knowledge to the creation of a global disease-agnostic public health surveillance network.